Скачать или смотреть Donanemab: Kya Alzheimer Kay berhnay Ko Rokne Wali Pehli Dawa Mil Gayi Hai? - Dr. Arham Shabbir

Kya Alzheimer ki progress ko roknay wali pehli dawa mil chuki hai? Donanemab ka naam har medical platform par chal raha hai — lekin kya yeh waqai mein game changer hai?

Iss video mein aapko milegi sirf authentic aur simplified medical explanation, bina kisi exaggeration ke. Har us shakhs ke liye zaroori jo memory loss, dementia, ya brain health ke issues se guzar raha hai.

📌 Agar aap reliable health education chahte hain to channel ko subscribe zaroor karein — aur comment mein batayein: kya aap pehli baar Donanemab ka naam sun rahe hain?

#Donanemab #alzheimersdisease #brainhealth #fdaapproved #medicalupdate #neurohealth #MemoryLossAwareness #dementiaawareness #medicalexplained #HealthPakistan #drarhamshabbir

References:
FDA (U.S. Food & Drug Administration) – Official approval of Donanemab (brand: Kisunla) for early Alzheimer’s disease treatment, July 2024.
Link: FDA.gov News Release

NEJM (New England Journal of Medicine) – "Donanemab in Early Alzheimer’s Disease" – TRAILBLAZER-ALZ 2 Phase 3 trial results.
DOI: 10.1056/NEJMoa2304841

ClinicalTrials.gov – Study Record: NCT04437511
Official trial registry documenting methodology, endpoints, and inclusion criteria.

Alzheimer’s Association (alz.org) – Latest updates on disease-modifying therapies and amyloid-targeting drugs.

Eli Lilly & Company – Donanemab manufacturer website and full prescribing information (PI).

Regards:
Dr. Arham Shabbir
B. Pharm; R. Ph; M. Phil; PhD (Pharmacology)